Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Background briefs
Filter     Order     Display # 
Date Item Title
01 Mar 2010 Approaches for prevention and treatment of S. aureus infections
14 Feb 2010 Targeting the cancer stem cells: Notch Signaling Pathway Inhbitors
07 Feb 2010 c-Met/HGF Inhibitors: Who missed the train?
31 Jan 2010 Target Hot Spot: Interleukin-17
17 Jan 2010 New technologies revive old targets: PSMA & PSA
10 Jan 2010 Broad evaluation of PDE-4 inhibitors as anti-inflammatory agents
13 Dec 2009 The business of tissue growth factors: more to come?
06 Dec 2009 The Concept of Neurotrophic Growth Factors: more than proteins
29 Nov 2009 Progress in the field of bone, dental, cartilage and tendon repair growth factors
22 Nov 2009 CXC Receptors and their Ligands: targets for inflammation and cancer
15 Nov 2009 Hsp90 Inhibition: a powerful therapeutic strategy in cancer R&D
07 Nov 2009 TGF and TGF-R: preferred target for biologics
01 Nov 2009 Fibroblast Growth Factor Signalling: a versatile target in many diseases
18 Oct 2009 What’s in the pipeline of recombinant and plasma-derived coagulation factors?
11 Oct 2009 The pipeline of PDGF-R agonists and antagonists
13 Sep 2009 EGF-R: from a specific target to a broader inhibition profile
06 Sep 2009 Advances in the pipeline of novel Her2 receptor targeting molecules
30 Aug 2009 VEGF and VEGF-R: a commercially and clinically successful target attracts numerous followers
23 Aug 2009 Novel Targets for specific therapy of hepatitis C
14 Aug 2009 A full pipeline coagulation factors is challenging the market leaders
02 Aug 2009 Clinical value of mitosis targets CHK and Eg5 still under evaluation
26 Jul 2009 Emerging pipeline of improved Bcr-Abl and/or Src kinase inhibitors
19 Jul 2009 PI3K-AKT-mTOR Pathway Inhibitors: Focus on isoforms and combinations
11 Jul 2009 HDAC Inhibitors: emerging drugs in oncology and other indications
04 Jul 2009 IGF-1R Antagonists revisited: broad clinical utility still under evaluation
28 Jun 2009 The next generation of immunotoxins: less immunogenic and more effective?
21 Jun 2009 Immunocytokines in clinical evaluation
14 Jun 2009 The maturation of antibody-drug conjugate technologies in oncology
07 Jun 2009 Novel Mitotic Kinase Inhibitors
31 May 2009 Advances in the field of Ras-Raf-MEK-ERK pathway inhibitors
24 May 2009 Novel anti-mitosis target Polo-like Kinase in clinical validation
17 May 2009 Inhibitors targeting mutant B-Raf promise greater therapeutic efficacy
10 May 2009 Next generation of neutrophil elastase inhibitors
04 May 2009 The promise of antagonists and agonists of NGF to treat neurologic diseases
20 Apr 2009 PARP Inhibitors: a targeted approach to treating solid tumors.
13 Apr 2009 Competitor Analysis: Sphingosine-1-Phosphate (S1P)
05 Apr 2009 EpCAM: old cancer target revisited
29 Mar 2009 What’s in the pipeline of treatments for amyotrophic lateral sclerosis?
22 Mar 2009 Successful T cell targeting via CD3 for autoinmune diseases and cancer
15 Mar 2009 A beefy market calls for non-stimulant ADHD treatments
08 Mar 2009 TNF antibodies beat them all in Biologics Sales 2008
02 Mar 2009 Finding the right indication for p38 MAPK inhibitors
21 Feb 2009 Advances in the treatment of wet and dry age-related macular degeneration (AMD)
15 Feb 2009 TNF Antagonists: most successful with plenty of competition in the pipeline
09 Feb 2009 Repositioning of interleukin-1 as an anti-inflammatory target
02 Feb 2009 Anti-IL-6/R Antagonists: new players in the rheumatoid arthritis market
26 Jan 2009 The next generation of anti-CD20 therapy: fine-tuning of rituximab
01 Dec 2008 Enzyme Replacement & Enhancement Therapies: a lucrative field for novel therapies
25 Nov 2008 Inteferon pipeline: crowded space of alpha IFN and opportunities for beta IFN
18 Nov 2008 The laborious way of innovation: SGLT inhibitors as a novel treatment of type 2 diabetes
 
<< Start < Prev 1 2 Next > End >>
Results 1 - 50 of 100

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics